Results 121 to 130 of about 5,469,182 (343)

Emerging role of ARHGAP29 in melanoma cell phenotype switching

open access: yesMolecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster   +3 more
wiley   +1 more source

Classification and advances in clinical research of artificial colloidal plasma substitutes

open access: yesZhongguo shuxue zazhi
The number of patients with reduced blood volume due to haemorrhage, fractures, severe infections, extensive burns and tumours is increasing, and traditional blood products are no longer able to meet the increasing clinical demand.
CHANG Zhengyang   +5 more
doaj   +1 more source

Ground principles of animal’s blood medication [PDF]

open access: yesMedicamentul Veterinar, 2008
In the paper ground principles of blood medication in animals are enumerated. There are presented animal's blood type groups (antigens and isoanticorps in dog and cat), auto transfusion in animals, blood substitutes (free hemoglobins, fluorocarbons ...
Cristina, T.Romeo
doaj  

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

open access: yesMolecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert   +13 more
wiley   +1 more source

Hemoglobin can Act as a (Pseudo)-Peroxidase in Vivo. What is the Evidence?

open access: yesFrontiers in Molecular Biosciences, 2022
Abdu I. Alayash, Michael T. Wilson
doaj   +1 more source

Faculty Profile: Herbert E. Cohn, MD, FACS [PDF]

open access: yes, 2013
One might say if you don’t know Dr. Herbert Cohn, you don’t really know Jefferson. Dr. Cohn arrived at Jefferson Medical College in 1951 as a medical student (JMC ’55).

core   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Small-Diameter Blood Vessel Substitutes: Biomimetic Approaches to Improve Patency

open access: yesBiomimetics
Small-dimeter blood vessels (
Jean-Marc Behr   +2 more
doaj   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

open access: yesMolecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy